A 340B hospital is a hospital that qualifies for the federal 340B Drug Pricing Program, which requires drug manufacturers to sell outpatient medications to eligible hospitals at significantly reduced prices. The program exists to help hospitals that serve large numbers of low-income and uninsured patients stretch their resources further. As of 2021, roughly 2,530 hospitals participated, representing nearly half of all community hospitals in the United States.
How the 340B Program Works
Congress created the 340B program in 1992 under the Veterans Health Care Act. The law added Section 340B to the Public Health Service Act, requiring any drug manufacturer that participates in Medicaid to offer covered outpatient drugs to qualifying healthcare providers at steep discounts. The original goal was straightforward: help safety-net providers “stretch scarce federal resources to reach more eligible patients or provide more comprehensive services.”
The program is overseen by the Health Resources and Services Administration (HRSA), a federal agency within the Department of Health and Human Services. Hospitals don’t receive a government subsidy. Instead, they purchase drugs directly from manufacturers (or through wholesalers) at a discounted “ceiling price” that the manufacturer is legally required to honor. The hospital can then dispense or administer those drugs to its patients, and the difference between what the hospital paid and what it receives in reimbursement from insurers becomes revenue the hospital can reinvest.
Which Hospitals Are Eligible
Not every hospital can join the 340B program. For-profit hospitals are excluded entirely. To qualify, a hospital must fall into one of six categories defined by federal law:
- Disproportionate share hospitals (DSH), which serve a high proportion of low-income patients
- Children’s hospitals
- Critical access hospitals, typically small rural facilities
- Free-standing cancer hospitals
- Rural referral centers
- Sole community hospitals, often the only hospital serving a geographic area
Disproportionate share hospitals are the largest group in the program and face an additional threshold: their DSH adjustment percentage, a Medicare metric reflecting how many low-income patients they treat, must be greater than 11.75% on their most recently filed cost report. Beyond that number, DSH hospitals must also meet one of three structural requirements. They must be owned or operated by a state or local government, be a public or private nonprofit that has been formally granted governmental powers, or be a private nonprofit hospital under contract with a government entity to provide care to low-income individuals who don’t qualify for Medicare or Medicaid.
How 340B Drug Prices Are Calculated
The discounted price a 340B hospital pays is called the “ceiling price,” and it’s set by a specific formula. HRSA calculates it by taking the drug’s Average Manufacturer Price (AMP) from the previous quarter and subtracting the Unit Rebate Amount, which is the same rebate calculation used in the Medicaid Drug Rebate Program. The result is rounded to two decimal places, and it can never go below one penny per unit.
For brand-name drugs, these discounts are substantial. Depending on the medication, a 340B hospital may pay 25% to 50% less than the standard wholesale price, and in some cases even more. Generic drugs tend to have smaller margins since their prices are already lower. When a new drug hits the market and doesn’t yet have an established AMP, the manufacturer must estimate a ceiling price using the wholesale acquisition cost minus the applicable rebate percentage until real pricing data becomes available, typically within about a year.
What Hospitals Must Do to Stay Compliant
Participating in the 340B program comes with serious compliance obligations. HRSA conducts audits that examine four core areas: whether the hospital still meets eligibility requirements, whether it’s following rules about group purchasing organizations, whether it has prevented “duplicate discounts” (claiming both a 340B price and a Medicaid rebate on the same drug), and whether it has prevented “diversion” (giving 340B drugs to patients who don’t qualify).
During an audit, HRSA reviews the hospital’s internal policies, tests a sample of drug transaction records, checks that outpatient clinics and contract pharmacies are operating correctly, and verifies that the hospital’s records are accurate. Hospitals that fail an audit must develop a corrective action plan and settle with affected manufacturers, usually within six months. Repeated violations of diversion rules can result in removal from the program entirely, with the hospital potentially barred from re-enrolling for a period of time.
The Contract Pharmacy Dispute
One of the biggest ongoing controversies in the 340B program involves contract pharmacies. Many 340B hospitals don’t have their own in-house pharmacy, so they partner with outside retail pharmacies to dispense 340B drugs to their patients. For years, manufacturers honored these arrangements without pushback. Starting around 2020, several major drug companies began restricting or refusing to ship 340B-priced drugs to contract pharmacies, arguing the original law never required them to do so.
The legal battles have largely sided with manufacturers on this point. In a key ruling, the Fourth Circuit Court of Appeals held that the 340B statute is “silent about delivery” and contract pharmacies. The law fixes only the price that manufacturers must offer to covered entities, leaving all other terms, including where and how drugs are delivered, open to negotiation. The court also struck down a West Virginia law that tried to force manufacturers to ship 340B drugs to unlimited contract pharmacies, ruling that such state mandates are preempted by the federal program. Congress designated HHS as the sole enforcer of the 340B program, and state laws that create their own enforcement schemes overstep that boundary.
For hospitals that depend heavily on contract pharmacy arrangements, particularly rural facilities without on-site pharmacies, these restrictions have created real operational challenges and reduced the financial benefit of the program.
The Scale of the Program Today
The 340B program has grown far beyond hospitals. When all entity types are counted, including federally qualified health centers, HIV/AIDS clinics, and other safety-net providers along with their associated sites, roughly 50,000 facilities participated in 2021. Hospital-based facilities, meaning hospitals and their off-site outpatient clinics, accounted for about 61% of that total.
The program generates billions of dollars in savings each year, and how hospitals use that money is a point of debate. Federal law does not dictate how 340B revenue must be spent. Hospitals often point to charity care, expanded services for uninsured patients, and subsidized clinics. Critics argue that some hospitals, particularly large systems that have acquired physician practices and outpatient clinics, use the program primarily as a revenue source without proportionally increasing services to vulnerable populations. This tension has made 340B reform a recurring topic in Congress, though no major legislative changes have passed in recent years.